FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours por responses	0.5								

	s of Reporting Persor		2. Issuer Name and Ticker or Trading Symbol Corvus Pharmaceuticals, Inc. [CRVS]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
MILLER RICHARD A MD			<u>corver manaceuteus, mer</u> [onvo]	Х	Director	10% Owner			
				x	Officer (give title	Other (specify			
(Last)	(First)	(Middle)	Date of Earliest Transaction (Month/Day/Year)		below)	below)			
CORVUS PHARMACEUTICALS, INC.			11/12/2019		President and CEO				
863 MITTEN RO	DAD, SUITE 102								
			4. If Amendment, Date of Original Filed (Month/Day/Year)		idual or Joint/Group Filing (C	Check Applicable			
(Street)				Line)					
BURLINGAME	СА	94010		X	Form filed by One Reporti	ng Person			
					Form filed by More than C Person	one Reporting			
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)				Disposed Of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150.4)	
Common Stock	11/12/2019		Р		272	A	\$2.9	1,163,779(1)	Ι	By Trust ⁽²⁾	
Common Stock	11/13/2019		Р		14,736	A	\$ 3.0022 ⁽³⁾	1,178,515(1)	Ι	By Trust ⁽²⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		Expiration Date		of Expiration Date Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		e Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Expiration Exercisable Date		Title	Amount or Number of Shares								

Explanation of Responses:

1. A portion of these shares is subject to a right of repurchase held by the Issuer.

2. These shares are held by Richard A. Miller and Sandra J. Horning, Trustees of the Miller-Horning Family Trust u/a/d January 25, 1985 (the "Miller-Horning Trust"). Dr. Miller has shared voting, investment and dispositive power over the shares held by the Miller Horning Trust.

3. The price reported in Column 4 is a weighted price. These Shares were purchased in multiple transactions at prices ranging from \$2.9543 to \$3.0194 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.

<u>/s/ Leiv Lea, as Attorney-in-</u>	11/14/2010
Fact for Richard A. Miller	<u>11/14/2019</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.